Developer docs
API playgroundTry for free, no card

Search company profiles

BioLab Sciences

Full company profile

uuid00skm1h

Namestring
BioLab Sciences
Legal namestring
BioLab Holdings, Inc.
Company typeenum
Private
Founded yearstring
-
Descriptiontext

BioLab Holdings, Inc., operating as BioLab Sciences, is a privately held medical device manufacturer headquartered in Mesa, Arizona that develops, manufactures, and commercializes wound care products. The company serves hospitals, clinics, wound care centers, healthcare distributors, and patients with chronic and acute wounds. Its portfolio is organized into two core families: the Microlyte line — featuring Microlyte SAM, a fully synthetic antimicrobial matrix, and Microlyte Painguard for pain management — and the Membranes line, which includes single and dual layer amnion membranes (Membrane Wrap, Membrane Wrap-Lite) plus a specialized Ocular Membrane. BioLab also offers APIs (Active Pharmaceutical Ingredients) as part of its broader medical manufacturing footprint.

The company's revenue model is anchored in proprietary medical device and tissue-based product sales. Pricing is not publicly disclosed and is inferred to be quote-based given the B2B/medical device context. Go-to-market blends a global healthcare distributor network (supported by a dedicated Distributor Portal) with direct enterprise field sales to healthcare providers, supported by patient-facing educational resources on the company's website. Customer segments span institutional buyers (Healthcare Providers, Healthcare Distributors) and end-user patients, reflecting a horizontal segmentation approach.

The company claims AATB (American Association of Tissue Banks) Accreditation and maintains strategic alliances with APIS, Terraplasma Medical, CureVision, and Imbed Biosciences. No founding date, funding history, headcount, management team composition, or disclosed financial metrics are available in the source data, which materially limits visibility into company scale, capital structure, and historical trajectory. BioLab's website is actively maintained and the company appears to be operating and growing, but the absence of publicly verifiable growth signals prevents definitive trajectory classification.

Short descriptiontext

BioLab Sciences is a privately held Mesa, Arizona-based medical device manufacturer that develops, produces, and distributes wound care products — including the Microlyte antimicrobial matrix line and amnion membrane products — to healthcare providers, distributors, and patients globally.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersMesa, United States
HQ citystring
Mesa
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
advanced wound care, amnion membrane products, antimicrobial wound matrices, tissue-based medical devices, active pharmaceutical ingredients
Industry2 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Medical Equipment and Supplies Manufacturing3391
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Surgical & Medical Instruments & Apparatus3841
Product category
Advanced Wound Care Products
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device and Wound Care Product Sales
TypeHardware Sales
Description

BioLab Holdings develops, manufactures, and commercializes wound care medical devices and tissue-based products. Revenue is generated through the sale of proprietary wound care products including Microlyte antimicrobial matrices and membrane products to healthcare distributors, providers, and patients.

biolabholdings.com
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

BioLab Holdings develops, manufactures, and commercializes wound care medical devices and tissue-based products. The portfolio centers on the Microlyte line of fully synthetic antimicrobial matrices (including Microlyte SAM and Microlyte Painguard) and amnion membrane products (Membrane Wrap, Membrane Wrap-Lite, and Ocular Membrane), with Active Pharmaceutical Ingredients (APIs) offered as an additional category. Products are sold to healthcare distributors and institutional providers for the treatment of chronic wounds and post-surgical wound management.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

BioLab Holdings is a medical manufacturing company that develops, manufactures, and commercializes wound care products. The product portfolio consists of two main categories: Microlyte Products (including Microlyte SAM, a fully synthetic antimicrobial matrix, and Microlyte Painguard) and Membranes (including Ocular Membrane, Membrane Wrap, and Membrane Wrap-Lite, which offer single and dual layer amnion membrane solutions). Additionally, the company offers APIs (Active Pharmaceutical Ingredients). The products are designed to optimize the standard of wound care through innovations grounded in science for treatment of chronic wounds.

Product and service6 records
1Microlyte SAM
CategoryAdvanced wound care — synthetic antimicrobial matrices
Description

Fully synthetic antimicrobial matrix designed for wound care applications, providing clinical performance for chronic wound treatment. Targeted at healthcare providers and distributors serving patients with chronic wounds.

2Microlyte Painguard
CategoryAdvanced wound care — synthetic antimicrobial matrices
Description

Antimicrobial wound care product within the Microlyte line, designed for pain management in wound care treatment. Targeted at healthcare providers treating patients with painful wounds.

3Membrane Wrap
CategoryTissue-based wound care membranes
Description

Dual layer amnion membrane product designed for enhanced wound coverage and healing. Targeted at healthcare providers treating chronic and complex wounds.

4Membrane Wrap - Lite
CategoryTissue-based wound care membranes
Description

Single layer amnion membrane product designed for wound coverage and healing. Targeted at healthcare providers treating wounds where a single layer membrane is indicated.

5Ocular Membrane
CategoryTissue-based ocular membranes
Description

Specialized membrane product designed for ocular applications within the membranes product line. Targeted at ophthalmologists and eye care specialists treating ocular wounds.

6APIs (Active Pharmaceutical Ingredients)
CategoryPharmaceutical ingredients manufacturing
Description

Active Pharmaceutical Ingredients (APIs) offered by BioLab Holdings as part of its medical manufacturing portfolio. Targeted at pharmaceutical and medical manufacturing customers.

Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierMinorTypeStrategic or Co-development Partner
Description

APIS appears as a partner/clinician-focused organization in the wound care space. The relationship appears to be collaborative in nature with joint clinical focus in wound care recovery.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Terraplasma Medical is a partner organization in the wound care/medical technology space. The partnership appears focused on advancing wound care solutions and medical technologies.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Imbed Biosciences is a partner organization in the wound care and biomedical space, suggesting potential collaboration on advanced wound care technologies and products.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Organogenesis is a leading regenerative medicine company selling skin substitutes (Apligraf, Dermagraft) and wound care biologics, competing head-to-head with BioLab's amnion membranes and antimicrobial matrices in advanced wound care.

TypeBroad incumbent
Description

Solventum's Health Care segment includes advanced wound care solutions (3M Veraflo, Promogran) with deep global distribution, competing with BioLab across hospital and home care wound management channels.

TypeBroad incumbent
Description

Integra LifeSciences offers regenerative tissue technologies and wound matrices (Integra Dermal Regeneration Template, PriMatrix) that overlap directly with BioLab's skin substitute and membrane categories.

TypeBroad incumbent
Description

Mölnlycke is a major global wound care and surgical solutions provider (Mepilex, Avance, Granudacyn), with broad hospital and distributor networks that compete with BioLab's membrane and antimicrobial portfolio.

TypeEmerging player
Description

Imbed Biosciences develops ultrathin antimicrobial wound matrices (Microlyte) - note this appears to share Microlyte branding with BioLab and is also listed as a partner, indicating closely related but competing/collaborating product technology in synthetic antimicrobial wound dressings.

TypeBroad incumbent
Description

Coloplast's Wound Care division offers a broad portfolio of advanced dressings, skin barriers, and specialty wound care products with global distribution, overlapping with BioLab's distributor-led wound care go-to-market.

TypeBroad incumbent
Description

ConvaTec provides advanced wound dressings, skin care products, and ostomy devices with strong hospital and homecare channels, competing with BioLab in chronic wound management and tissue-based products.

TypeBroad incumbent
Description

Smith+Nephew's Advanced Wound Management portfolio (Allevyn, PICO, nanOscale) is one of the largest global wound care franchises, competing across dressings, NPWT, and advanced biologics relevant to BioLab's chronic wound offerings.

TypeOthers
Description

Cardinal Health is a major medical product distributor and manufacturer with wound care offerings, representing both a potential channel partner and adjacent competitor to BioLab's distributor-led go-to-market model.

TypeDirect peer
Description

MiMedx develops and distributes placental/amnion membrane allografts (e.g., EpiFix, AmnioFix) for chronic wound care and surgical recovery, directly overlapping with BioLab's Membrane Wrap product line and skin substitute positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BioLab Sciences

Advanced Wound Care Productsbiolabsciences.net

BioLab Sciences is a privately held Mesa, Arizona-based medical device manufacturer that develops, produces, and distributes wound care products — including the Microlyte antimicrobial matrix line and amnion membrane products — to healthcare providers, distributors, and patients globally.

What BioLab Sciences does

BioLab Holdings, Inc., operating as BioLab Sciences, is a privately held medical device manufacturer headquartered in Mesa, Arizona that develops, manufactures, and commercializes wound care products. The company serves hospitals, clinics, wound care centers, healthcare distributors, and patients with chronic and acute wounds. Its portfolio is organized into two core families: the Microlyte line — featuring Microlyte SAM, a fully synthetic antimicrobial matrix, and Microlyte Painguard for pain management — and the Membranes line, which includes single and dual layer amnion membranes (Membrane Wrap, Membrane Wrap-Lite) plus a specialized Ocular Membrane. BioLab also offers APIs (Active Pharmaceutical Ingredients) as part of its broader medical manufacturing footprint.

The company's revenue model is anchored in proprietary medical device and tissue-based product sales. Pricing is not publicly disclosed and is inferred to be quote-based given the B2B/medical device context. Go-to-market blends a global healthcare distributor network (supported by a dedicated Distributor Portal) with direct enterprise field sales to healthcare providers, supported by patient-facing educational resources on the company's website. Customer segments span institutional buyers (Healthcare Providers, Healthcare Distributors) and end-user patients, reflecting a horizontal segmentation approach.

The company claims AATB (American Association of Tissue Banks) Accreditation and maintains strategic alliances with APIS, Terraplasma Medical, CureVision, and Imbed Biosciences. No founding date, funding history, headcount, management team composition, or disclosed financial metrics are available in the source data, which materially limits visibility into company scale, capital structure, and historical trajectory. BioLab's website is actively maintained and the company appears to be operating and growing, but the absence of publicly verifiable growth signals prevents definitive trajectory classification.

BioLab Sciences firmographics

Firmographics
Name
BioLab Sciences
Legal name
BioLab Holdings, Inc.
Website
https://biolabsciences.net
Company type
Private
Operating status
Operating
Short description
BioLab Sciences is a privately held Mesa, Arizona-based medical device manufacturer that develops, produces, and distributes wound care products — including the Microlyte antimicrobial matrix line and amnion membrane products — to healthcare providers, distributors, and patients globally.
Ownership category
akta.pro rank

BioLab Sciences industry classification

Industry
Product category
Advanced Wound Care Products
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Medical Equipment and Supplies Manufacturing (3391)
SIC
Biological Products, (No Disgnostic Substances) (2836), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAG
Wound Healing & Skin Regeneration (advanced dressings, skin substitutes)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering

Keywords

  • Advanced wound care
  • Amnion membrane products
  • Antimicrobial wound matrices
  • Tissue-based medical devices
  • Active pharmaceutical ingredients

Where BioLab Sciences is headquartered

Location

Headquarters

HQ city
Mesa
HQ country
United States
HQ region
North America

Offices1 record

Markets served

BioLab Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales

Revenue model

  1. Medical Device and Wound Care Product Sales: BioLab Holdings develops, manufactures, and commercializes wound care medical devices and tissue-based products. Revenue is generated through the sale of proprietary wound care products including Microlyte antimicrobial matrices and membrane products to healthcare distributors, providers, and patients.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels1 record

BioLab Sciences product offering

Product offering

Core offering

BioLab Holdings develops, manufactures, and commercializes wound care medical devices and tissue-based products. The portfolio centers on the Microlyte line of fully synthetic antimicrobial matrices (including Microlyte SAM and Microlyte Painguard) and amnion membrane products (Membrane Wrap, Membrane Wrap-Lite, and Ocular Membrane), with Active Pharmaceutical Ingredients (APIs) offered as an additional category. Products are sold to healthcare distributors and institutional providers for the treatment of chronic wounds and post-surgical wound management.

Product overview

BioLab Holdings is a medical manufacturing company that develops, manufactures, and commercializes wound care products. The product portfolio consists of two main categories: Microlyte Products (including Microlyte SAM, a fully synthetic antimicrobial matrix, and Microlyte Painguard) and Membranes (including Ocular Membrane, Membrane Wrap, and Membrane Wrap-Lite, which offer single and dual layer amnion membrane solutions). Additionally, the company offers APIs (Active Pharmaceutical Ingredients). The products are designed to optimize the standard of wound care through innovations grounded in science for treatment of chronic wounds.

Differentiator

Problem solved

Functional benefit

Products and services

  • Microlyte SAM Fully synthetic antimicrobial matrix designed for wound care applications, providing clinical performance for chronic wound treatment. Targeted at healthcare providers and distributors serving patients with chronic wounds.
  • Microlyte Painguard Antimicrobial wound care product within the Microlyte line, designed for pain management in wound care treatment. Targeted at healthcare providers treating patients with painful wounds.
  • Membrane Wrap Dual layer amnion membrane product designed for enhanced wound coverage and healing. Targeted at healthcare providers treating chronic and complex wounds.
  • Membrane Wrap - Lite Single layer amnion membrane product designed for wound coverage and healing. Targeted at healthcare providers treating wounds where a single layer membrane is indicated.
  • Ocular Membrane Specialized membrane product designed for ocular applications within the membranes product line. Targeted at ophthalmologists and eye care specialists treating ocular wounds.
  • APIs (Active Pharmaceutical Ingredients) Active Pharmaceutical Ingredients (APIs) offered by BioLab Holdings as part of its medical manufacturing portfolio. Targeted at pharmaceutical and medical manufacturing customers.

Companies that use BioLab Sciences

Customer profile

Segments3 records

Ideal customer profiles2 records

BioLab Sciences technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

BioLab Sciences partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered minor.

  • APIS (recoverwithapis.com)minorStrategic or Co-development PartnerAPIS appears as a partner/clinician-focused organization in the wound care space. The relationship appears to be collaborative in nature with joint clinical focus in wound care recovery.
  • Terraplasma MedicalminorStrategic or Co-development PartnerTerraplasma Medical is a partner organization in the wound care/medical technology space. The partnership appears focused on advancing wound care solutions and medical technologies.
  • Imbed BiosciencesminorStrategic or Co-development PartnerImbed Biosciences is a partner organization in the wound care and biomedical space, suggesting potential collaboration on advanced wound care technologies and products.

Scale indicators1 record

Recent moves6 records

Expansion highlights4 records

BioLab Sciences competitors and assessment

Company assessment

Direct peers

  • Organogenesis: Organogenesis is a leading regenerative medicine company selling skin substitutes (Apligraf, Dermagraft) and wound care biologics, competing head-to-head with BioLab's amnion membranes and antimicrobial matrices in advanced wound care.
  • MiMedx Group: MiMedx develops and distributes placental/amnion membrane allografts (e.g., EpiFix, AmnioFix) for chronic wound care and surgical recovery, directly overlapping with BioLab's Membrane Wrap product line and skin substitute positioning.

Broad incumbents

  • Solventum (formerly 3M Health Care): Solventum's Health Care segment includes advanced wound care solutions (3M Veraflo, Promogran) with deep global distribution, competing with BioLab across hospital and home care wound management channels.
  • Integra LifeSciences: Integra LifeSciences offers regenerative tissue technologies and wound matrices (Integra Dermal Regeneration Template, PriMatrix) that overlap directly with BioLab's skin substitute and membrane categories.
  • Mölnlycke Health Care: Mölnlycke is a major global wound care and surgical solutions provider (Mepilex, Avance, Granudacyn), with broad hospital and distributor networks that compete with BioLab's membrane and antimicrobial portfolio.
  • Coloplast: Coloplast's Wound Care division offers a broad portfolio of advanced dressings, skin barriers, and specialty wound care products with global distribution, overlapping with BioLab's distributor-led wound care go-to-market.
  • ConvaTec: ConvaTec provides advanced wound dressings, skin care products, and ostomy devices with strong hospital and homecare channels, competing with BioLab in chronic wound management and tissue-based products.
  • Smith+Nephew: Smith+Nephew's Advanced Wound Management portfolio (Allevyn, PICO, nanOscale) is one of the largest global wound care franchises, competing across dressings, NPWT, and advanced biologics relevant to BioLab's chronic wound offerings.

Emerging players

  • Imbed Biosciences: Imbed Biosciences develops ultrathin antimicrobial wound matrices (Microlyte) - note this appears to share Microlyte branding with BioLab and is also listed as a partner, indicating closely related but competing/collaborating product technology in synthetic antimicrobial wound dressings.

Others

  • Cardinal Health (Medical Products): Cardinal Health is a major medical product distributor and manufacturer with wound care offerings, representing both a potential channel partner and adjacent competitor to BioLab's distributor-led go-to-market model.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

BioLab Sciences social profiles

Digital presence

BioLab Sciences compliance and trust

Trust signal

Compliance1 record

BioLab Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BioLab Sciences leadership team

Management profile

Number of profiles

BioLab Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BioLab Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BioLab Sciences

What does BioLab Sciences do?

BioLab Holdings develops, manufactures, and commercializes wound care medical devices and tissue-based products. The portfolio centers on the Microlyte line of fully synthetic antimicrobial matrices (including Microlyte SAM and Microlyte Painguard) and amnion membrane products (Membrane Wrap, Membrane Wrap-Lite, and Ocular Membrane), with Active Pharmaceutical Ingredients (APIs) offered as an additional category. Products are sold to healthcare distributors and institutional providers for the treatment of chronic wounds and post-surgical wound management.

Is BioLab Sciences a public or private company?

BioLab Sciences is a private company. It is classified as unknown and is currently operating.

When was BioLab Sciences founded?

BioLab Sciences was founded in -1.

Where is BioLab Sciences based?

BioLab Sciences is headquartered in Mesa, United States, in the North America region.

How does BioLab Sciences make money?

One revenue line is on record: medical Device and Wound Care Product Sales.

Who are BioLab Sciences's main competitors?

Direct peers on record are Organogenesis and MiMedx Group. Broad incumbents are Solventum (formerly 3M Health Care), Integra LifeSciences, Mölnlycke Health Care, Coloplast, ConvaTec and Smith+Nephew. Imbed Biosciences is listed as an emerging player. Cardinal Health (Medical Products) is listed as an others.

Does BioLab Sciences have an API?

No public API is recorded for BioLab Sciences.

What industry is BioLab Sciences in?

BioLab Sciences's product category is Advanced Wound Care Products. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAG, Wound Healing & Skin Regeneration (advanced dressings, skin substitutes). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business Wire BlogThe Tissue Reference Group at the FDA, Recognizes BioLab Sciences Membrane Wrap – Hydro™ as an HCT/PThe FDA's Tissue Reference Group recognized BioLab Sciences' Membrane Wrap – Hydro, a hydrated human amnion membrane allograft, as a human cell, tissue, or cellular or tissue-based product. The recognition may streamline reimbursement for providers treating burns, surgical wounds, and chronic ulcers.Business Wire BlogBioLab Sciences Dermistat™ is Changing Wound Healing for DermatologistsBioLab Sciences' Dermistat, a regenerative biotechnology, is being used by dermatologists to accelerate healing in Mohs-related surgical wounds. It creates an autologous skin graft in 48 hours, reducing healing time to as little as three weeks. The therapy is on track to disrupt the wound care industry.Business Wire BlogBioLab Sciences Dermistat™ is Changing the Wound Care MarketBioLab Sciences introduced Dermistat, a regenerative therapy that uses a patient's own skin cells to create a gel-like autologous skin graft in 48 hours. It is used for post-Mohs wounds, burns, and chronic ulcers, and is on track to disrupt the wound care industry.Arizona Daily StarBioLab Sciences Acquires Intellectual Property for Transformative Wound Care TechnologyBioLab Sciences acquired intellectual property for MyOwn Skin, a non-surgical biotechnology that produces up to three 4-inch skin grafts from a small skin sample within a week. The technology, developed in 2012, has been used to treat severe burns, chronic wounds, and diabetic foot ulcers, and was named Top 10 Wound Care Solution Provider in 2019.PR NewswireArizona-based biotech startup BioLab Sciences announces patent for regenerative tissue therapy, MyOwn Skin™BioLab Sciences announced its exclusively licensed MyOwn Skin technology, a painless procedure using a patient's own skin to produce full-thickness grafts in 5-7 days. The company expects revenue of $4 million in 2019, rising to $15 million in 2020 and $120 million by 2023.